None listed
Conditions
Interventions
Medical Device : Treatment group: For active treatment, bilateral PC5, PC6, ST36, ST37, KI3 and SP6 will be stimulated for 30 minutes per day for 5 days using disposable, sterile needles inserted to a
Sponsors
Kyung Hee University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Aged over 40 years with written informed consent (2) Acute heart failure patient presenting dyspnea related to cardiogenic pulmonary edema and in need of diuretic treatment (3) Systolic blood pressure > 95 mmHg at admission (4) B-type natriuretic peptide(BNP) > 150 pg/mL or N-terminal pro b-type natriuretic peptide (NT-proBNP) >600 pg/mL
Exclusion criteria
Exclusion criteria: (1) Body temperature over 38.0? or in need of IV antibiotic treatment due to acute inflammation or sepsis (2) K < 3.5mEq/L (patients with potassium 3.0~3.5mEq/L may be admitted if they agree to receive K+ treatment) (3) Currently taking or planning to take vasopressors, inotropics, intra-aortic balloon pump, extracorporeal membrane oxygenation, endotracheal intubation. (4) Requiring heart transplant (5) Presenting with possibility of acute coronary syndrome within 2 weeks (6) Acute heart failure related to significant arrhythmia (ventriculr fibrillation, ventricular tachycardia, atrial fibrillation, atrial flutter, complete AV block) (7) Acute heart failure related to acute myocarditis, hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive cardiomyopathy (8) In need of / currently receiving hemodialysis, peritoneal dialysis (9) Abnormal liver function (Total bilirubin > 3mg/dL, albumin < 2.8mg/dL) (10) In need of blood transfusion (Hemoglobin < 8g/dL ?? hematocrit < 25%) (11) Chronic obstructive pulmonary disease (12) Currently undergoing treatment or has history of malignant tumor (13) Pregnant, Breast-feeding (14) Unable to follow up (outpatient clinic) for more than 6 months (15) Currently admitted in other clinical trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Difference in accumulative diuretic use from date of admission to date of discharge from symptom remission | — |
Secondary
| Measure | Time frame |
|---|---|
| Complete blood cell count, Blood urea nitrogen, Creatinine, Electroryte, Total bilirubin, Glucose, Total Protein, Albumin, AST(aspartate aminotransferase), ALT(alanine aminotransferase);Heart failure symptoms and adverse event ;Total admission period due to heart failure;EQ-5D(EuroQol five dimensions questionnaire), Minnesota Living with Heart Failure Questionnaire;Cardiac biomarker : Atrial natriuretic peptide (ANP), ST2 cardiac biomarker, Catecholamine, Vasoactive intestinal peptiede (VIP), Interleukin 6 (IL-6), Vascular adhesion protein-1 (VAP-1);Electrocardiograpy, Heart Rate Variability;Cardiac Function (Echocardiography);Cardiac or kidney related death (Major Adverse Cardiac Event, MACE);N-terminal pro b-type natriuretic peptide(NT-proBNP), high-sensitivity C-reactive protein (hsCRP) | — |
Countries
Korea, Republic of
Contacts
Public ContactJungtae Leem
Kyung Hee University
Outcome results
None listed